Stifel upgraded LeMaitre to Buy from Hold with a price target of $75, up from $59. The firm sees multiple top-line growth-enhancing and margin-expanding initiatives as indicative of the company’s now more-evolved, compelling, and sustainable growth and profitability outlook. Underpinning this outlook, the company appears well-positioned for continued price increases, strong margin expansion, and steady sales force additions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT:
- LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
- LeMaitre to Present at the 23rd Annual Needham Virtual Healthcare Conference
- LeMaitre to Participate at Upcoming Investor Conferences in March
- LeMaitre price target raised to $69 from $66 at Barrington
- LeMaitre price target raised to $72 from $60 at JMP Securities
